Hisamitsu Pharmaceutical Co., Inc.
HTSUF · OTC
2/28/2025 | 2/28/2024 | 2/28/2023 | 2/28/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.20 | 0.94 | 1.16 | 6.71 |
| FCF Yield | 1.83% | 1.72% | 1.45% | 4.59% |
| EV / EBITDA | 4.61 | 7.73 | 12.84 | 11.57 |
| Quality | ||||
| ROIC | 4.94% | 3.48% | 3.20% | 2.61% |
| Gross Margin | 58.46% | 55.73% | 56.65% | 58.30% |
| Cash Conversion Ratio | 0.65 | 1.30 | 0.79 | 1.48 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.73% | 5.64% | 3.87% | -5.18% |
| Free Cash Flow Growth | -3.13% | 6.91% | -67.89% | 689.37% |
| Safety | ||||
| Net Debt / EBITDA | -3.16 | -4.53 | -7.24 | -7.33 |
| Interest Coverage | 821.52 | 731.50 | 773.27 | 466.85 |
| Efficiency | ||||
| Inventory Turnover | 2.89 | 2.96 | 2.94 | 3.05 |
| Cash Conversion Cycle | 180.78 | 177.99 | 139.34 | 138.94 |